Finally, a recently published study in a large US based hospital database found a reduction in all‐cause death (as well as stroke and venous thromboembolism) in patients taking PDE5 inhibitors, consistent with our findings [29]. This evidence concerns the gene PDE5A and venous thromboembolism.